石药集团(01093.HK)拟不超1.2亿元获得上海创诺盐酸厄洛替尼原料药及片剂的商业化权利
格隆汇11月7日丨石药集团(01093.HK)公布,公司附属公司石药集团欧意药业有限公司已与上海创诺制药有限公司订立协议,内容有关上海创诺开发的盐酸厄洛替尼原料药及片剂的产品转让。该产品已获中国国家药品监督管理局颁发药品注册批件,为国内该品种首家获批的仿制药,并已收录到中国上市药品目录集中,视同通过一致性评价。
根据该协议,石药欧意将获得上海创诺转让该产品于中国(不包括香港、澳门及台湾)进行该产品有关的商业化及后续开发的独家权利(包括完整所有权和知识产权),并成为该产品上市许可持有人。作为转让的代价,石药欧意同意向上海创诺支付最多人民币1.2亿元的技术转让里程碑付款。石药欧意亦同意根据该产品于该地区销售额向上海创诺支付销售提成,为期十年。
据悉,盐酸厄洛替尼片为口服制剂,通过抑制肿瘤细胞配体依赖的HER-1/表皮生长因子受体(EGFR)的活性,达到抑制肿瘤细胞增殖的作用。获批适应症为适用于EGFR基因具有敏感突变的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗,包括一綫治疗、维持治疗,或既往接受过至少一次化疗进展后的二綫及以上治疗。盐酸厄洛替尼片为《国家基本医疗保险、工伤保险和生育保险药品目录》医保乙类品种。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.